As of January 22, 2025, Verve Therapeutics (VERV) has a market cap of $0.66 billion USD. According to our data, Verve Therapeutics is ranked No.5769 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.66 B |
38.30%
|
Dec 31, 2024 | $0.48 B |
-59.54%
|
Dec 29, 2023 | $1.18 B |
-27.96%
|
Dec 30, 2022 | $1.64 B |
-47.52%
|
Dec 31, 2021 | $3.12 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
REGENXBIO
RGNX
|
$0.39 B |
-0.000 M
|
USA
|
Precision BioSciences
DTIL
|
$38.13 M |
0.000 M
|
USA
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Rocket Pharmaceuticals
RCKT
|
$1.11 B |
-0.000 M
|
USA
|
Passage Bio
PASG
|
$36.81 M |
0.000 M
|
USA
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Market Cap | = | VERV Stock Price | * | VERV Shares Outstanding |
= | $7.80 | * | 84.66 M | |
= | $0.66 B |